Company says prostate cancer vaccine shows promise

Apr 14, 2009

(AP) -- The maker of an experimental treatment for prostate cancer says the vaccine has met a key goal in a late-stage study.

Seattle-based Dendreon Corp. said Tuesday that its Provenge vaccine improved overall survival when compared to a dummy treatment in a study of 512 men. The treatment is the first to use the body's immune system.

The study has been closely watched. Advisers to the Food and Drug Administration had previously recommended approval of the vaccine. But the FDA asked for more data. That sparked protests from men's groups and cancer advocates.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Two studies of cannabidiol oil as a treatment for severe, intractable seizures

add to favorites email to friend print save as pdf

Related Stories

Prostate cancer vaccines more effective with hormone therapy

Jul 10, 2008

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, ...

Cancer vaccine may be possibility

Feb 24, 2006

Researchers at the University of Washington and the Fred Hutchinson Cancer Center are working on a vaccine to prevent cancer.

Breakthrough vaccine to treat chemo-resistant ovarian cancer

Mar 08, 2007

Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will ...

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

Mar 03, 2015

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.